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Objectives: The objective of this study is to assess the acceptance of morbidity 
endpoints by the Institute for Quality and Efficiency in Healthcare (IQWiG) within 
the early benefit assessment in Germany. The analysis focuses on morbidity end-
points (ME) for oncology substances compared to non-oncology substances: (1) 
how many ME have been accepted? (2) In how many cases has IQWiG determined 
an additional benefit based on ME? MethOds: All benefit assessments published 
by the Federal Joint Committee (G-BA) between 01/01/2011 and 12/05/2015 have 
been considered (n= 126). Of those, 80 were excluded from the analysis due to 
one of the following reasons: orphan drug designation, no dossier submitted or 
incomplete evaluation by the IQWiG (due to missing data). Data analyzed: num-
ber of accepted ME as proportion of all submitted endpoints; additional benefit 
based on accepted ME; percent of assessments in which at least one ME was 
accepted. Results: In total, 19 oncology and 27 non-oncology assessments 
have been included into the analysis. For the 19 oncology assessments, a total 
of 76 ME had been submitted. IQWiG accepted hereof 20 ME (≈26%). Accepted ME 
include: pain, skeletal-related complications and symptoms. The IQWiG deter-
mined an additional benefit for six assessments based on ME (6/19≈32%). For the 
27 non-oncology assessments, 127 ME had been submitted. IQWiG accepted 79 
(≈62%) including: strokes, cardiovascular events and relapse-related events. For 
non-oncology substances, IQWiG determined an additional benefit for thirteen 
assessments based on ME (13/27≈48%). At least one endpoint was accepted in 
83% of oncology assessments and in 100% of benefit assessments in all other 
indications. cOnclusiOns: Though the rate of accepting ME in oncology indica-
tions is numerically lower (32% vs. 48%), the difference does not reach statistical 
significance (p= 0.36 Fisher’s exact test).
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Objectives: Multiple myeloma patients often experience adverse events 
(AEs) related to treatment with novel therapies or traditional chemotherapy. 
Observational studies frequently use administrative claims data or electronic medi-
cal records (EMR) to assess potential AEs. The purpose of this analysis is to compare 
the occurrence of AEs identified in claims data with those recorded in an oncol-
ogy EMR. MethOds: Multiple myeloma cases (n= 278) in the MarketScan Oncology 
EMR-Claims Linked Dataset who received novel or traditional chemotherapy were 
included. The index date was the first date of medication administration/order and 
patients were followed for AEs, including neutropenia, thrombocytopenia, venous 
thromboembolism (VTE) and diarrhea, until a > = 90 gap in all medications for the 
first regimen. Results: Neutropenia and thrombocytopenia were recorded less 
often in claims (neutropenia 9%; thrombocytopenia 7%) compared to EMR data 
(neutropenia 12%; thrombocytopenia 11%). Neutropenia and thrombocytopenia are 
monitored by oncologists with lab values and this may lead to more frequent record-
ing of less severe AEs in the EMR not reflected in claims data. VTE and diarrhea were 
recorded more often in the claims (VTE 9%; diarrhea 7%) compared to the EMR (VTE 
4%; diarrhea 4%). A VTE diagnosis may likely result in hospitalization and patients 
with diarrhea may seek care outside of their oncology practice; hence, claims data 
may capture additional diagnoses assigned by clinicians other than oncologists. 
Overall, the highest proportions of AEs were found with the linked data contain-
ing both the claims and EMR (neutropenia 19%, thrombocytopenia 16%, VTE 10%, 
diarrhea 11%). cOnclusiOns: AEs typically monitored by lab values ordered by 
oncologists were recorded more often in EMR data and AEs potentially diagnosed by 
clinicians in settings outside the oncology practice were recorded more often in the 
claims data. The linked claims-EMR data provided the most complete assessment 
of potential treatment-related AEs.
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Objectives: There is a growing call for the use of endonodal trials within network 
meta-analyses (NMA), such as for informative priors or improved connectivity. 
Endonodal trials can also be used to further inform arm-specific meta-regression 
coefficients, which may be used to simplify node definitions in combination therapy. 
We applied this concept to a network of first line antiretroviral therapy (ART) to 
determine if efavirenz (EFV) still belongs in the preferred regimen. MethOds: We 
conducted a systematic search of electronic databases up to March 1, 2015. Nodes 
were defined as specific antivirals rather than ART regimens, which simplified 
interpretation of modeling and results. Backbone regimens were categorized and 
arm-specific meta-regression used to adjust estimates accordingly. The alterna-
tive approach was to simply reduce the evidence base to trials that did not differ 
with respect to backbones. The most notable trial to differ in backbones was the 
SINGLE trial comparing EFV to dolutegravir (DTG), central to the research ques-
tion. Results: A total of 71 trials with 35,270 randomized patients informed the 
evidence base. DTG was found to be superior with respect to viral suppression at all 
time points (odds ratio [OR]: 1.87 at 48 weeks; 95% credible interval [CrI]: 1.34 – 2.64). 
Both DTG (OR: 0.26; 95% CrI: 0.15, 0.44) and low-dose EFV (OR: 0.39; 95% CrI: 0.17, 0.83) 
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Objectives: The decision to utilize a particular product may depend on for-
mal hospital guidelines, physician practice patterns, negotiated reimbursement 
schedules with insurance companies, and other local (geographic and/or hospi-
tal) characteristics. These elements are mostly unobservable for the purpose of 
statistical inference. A hospital fixed-effects model specification, in essence, con-
trols for unobservable within-hospital time-invariant characteristics. Focusing on 
the relationship between iso-osmolar contrast media (CM) and low-osmolar CM 
agents (LOCM) and renal failure events in patients undergoing inpatient inter-
ventional procedures, this study highlights the importance of controlling for such 
factors by comparing statistical specifications with and without hospital fixed-
effects. MethOds: The Premier database was used to identify patients between 
January 2008 and September 2013. Eligible patients had a primary procedure of 
angioplasty defined by International Classification of Diseases, 9th Revision (ICD-
9) and/or Current Procedural Terminology (CPT®) codes, inpatient admission, and 
LOCM or iso-osmolar CM agent. Renal failure during the visit was determined by 
ICD-9 diagnosis codes. Two different statistical approaches were employed to assess 
the relationship between renal failure and CM use – Ordinary Least Squares (OLS) 
cross-sectional and hospital fixed-effects model specification. Results: A total of 
385,290 interventional procedure visits met the inclusion criteria. The unadjusted 
univariate analysis showed 1.7% (p< 0.01) more renal events in the iso-osmolar 
CM cohort compared to LOCM. The most saturated (OLS) cross-sectional analysis 
showed 1.4% (p< 0.01) fewer renal events in the iso-osmolar CM cohort compared 
to patients who received LOCM. Controlling for unobserved heterogeneity across 
hospitals using the most saturated hospital fixed-effect specification, we found 
2.3% (p < 0.01) fewer renal failure events with iso-osmolar CM. cOnclusiOns: This 
study illustrated the importance of controlling for observable and for unobserv-
able, within-hospital time invariant characteristics through a hospital fixed-effects 
specification when the decision-making factors for selection of CM may vary from 
hospital to hospital.
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Objectives: Alzheimer’s disease (AD), the most common form of dementia, is a 
degenerative disorder of the brain that leads to memory loss. Oxidative stress is a 
hallmark of AD. This study aims to identify the genetic alterations of AD by using the 
conventional cytogenetic technique by Trypsin G- banding and molecular analysis 
of presenilin 1 (PS1) genotype by PCR. The role of selected ions related to energy 
metabolism as a consequence of oxidative stress in the deterioration accompa-
nied in AD patients were also analyzed. MethOds: The present study includes 
49 AD patients and the subjects were categorized in two groups (14 Early-Onset 
AD) patients and (31 Late- Onset AD) patients, in order to investigate the possible 
cytogenetic and molecular damage. The gels were developed by staining with silver 
nitrate. Results: The Late- Onset AD patient shows higher total CA level when 
compared to Early-Onset AD patient. A comparison of the frequencies for PS1 geno-
types among the Early-Onset AD and Late- Onset AD subjects demonstrated a sig-
nificant difference between the two groups. cOnclusiOns: The strong association 
of PS1 with Late- Onset AD patients called attention to the importance of genetic 
studies in AD and the possible roles of PS1 in the progression of this disease. Based 
on the contributing effects of PS1 in AD pathogenesis, targeting PS1 may provide new 
opportunities for AD therapeutic strategies. Key Words: Early-Onset Alzheimer’s 
disease patient, Late- Onset Alzheimer’s disease patients, PS1, PCR – RFLP
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Objectives: To compare physicians and patient’s reports of health resource uti-
lisation using the PGRx-3 datasets. MethOds: PGRx (Pharmacoepidemiologic 
General Research eXtension) is a multiusers, multi-countries, prospective Real 
World Datasets originally assembled for effectiveness and relative risk of medicines 
research. In 2015, PGRx was extended to HEOR research in six countries (France, 
UK, Italy, Germany, Spain and in the US). Diseases studied with the PGRx meth-
odology are: acute coronary syndrome, arrhythmias, stroke, lupus, rheumatoid 
arthritis, multiple sclerosis, Guillain Barré Syndrome, type I diabetes, autoimmune 
thyroiditis, depression and suicide attempts, paediatric autoimmune disorders, 
breast cancer, prostate cancer (on-going) and others. Patients are recruited by board-
certified specialists or general practitioners and they can fill self-questionnaires. 
More than 65% consenting patients also undergo a telephone interview. All PGRx 
datasets are submitted for ethics and privacy protection committees’ approval in 
the contemplated countries. Medical records of more than 5,000 patients have been 
obtained in a series of validation studies including several of the PGRx disorders and 
results compared to interviews of the same patients on health resources and drug 
utilisation. Results: An agreement superior to 95% between patients and their 
physician’s medical records was observed for report of chronic drug use and vac-
cines, but the agreement was low (< 30%) for drugs available OTC or in the patients’ 
pharmacy (eg: NSAIDs) and for patients’ health resources utilisation (eg: physician 
visits) (agreement less than 25%). cOnclusiOns: Physicians have poor knowledge 
of acute drug use and of health resource utilisation by patients. Patient interviews 
are more valid sources of information for health economics and outcomes research 
than chart reviews
